Phase | Title | Treatment | Primary Outcome | Enrollmenta | Status | NCT Number |
---|---|---|---|---|---|---|
I | Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation | Furmonertinib | ORR | 30 | Recruiting | NCT04858958 |
I/II | A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors. | BDTX-189 | Phase II:ORR | 200 | Recruiting | NCT04209465 |
I/II | A Phase 1/2a Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer | CLN-081 | Safety and Tolerability | 80 | Recruiting | NCT04036682 |
I/II | Assessing an Oral EGFR Inhibitor, DZD9008 in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) | DZD9008 | Part B:ORR | 220 | Recruiting | NCT03974022 |
I/II | A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer | FWD1509 | Safety and Tolerability | 130 | Recruiting | NCT05068024 |
I/II | Study of Poziotinib in Japanese Patients With NSCLC | Poziotinib | Phase II:ORR | 76 | Recruiting | NCT04402008 |
I/II | A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer | TAK-788 | ORR | 395 | Recruiting | NCT02716116 |
II | Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer | Afatinib plus cetuximab | DCR after 18 weeks | 37 | Recruiting | NCT03727724 |
II | Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II Trial | Almonertinib | ORR | 53 | Not yet recruiting | NCT04553887 |
II | Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer | Amivantamab | ORR and DOR | 780 | Recruiting | NCT02609776 |
II | First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2) | BAY2927088 | Safety and Tolerability | 250 | Not yet recruiting | NCT05099172 |
II | Dacomitinib in Lung Cancer With Uncommon EGFR Mutations | Dacomitinib | ORR | 30 | Recruiting | NCT04504071 |
II | Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer | JMT101 Combined With Afatinib (or Osimertinib) | Safety | 48 | Recruiting | NCT04448379 |
II | A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer | Lazertinib and Amivantamab | Safety and Tolerability | 520 | Recruiting | NCT04077463 |
II | A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations | Osimertinib | ORR | 37 | Recruiting | NCT03434418 |
II | Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer | Osimertinib combined with Bevacizumab | PFS | 20 | Recruiting | NCT04974879 |
II | Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC | Poziotinib | ORR | 80 | Recruiting | NCT03066206 |
II | Phase 2 Study of Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation | Poziotinib | ORR | 603 | Recruiting | NCT03318939 |
II | Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer | Poziotinib and Ramucirumab | PFS | 36 | Not yet recruiting | NCT05045404 |
II | Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions | Tarloxotinib | ORR | 60 | Terminated | NCT03805841 |
II/III | A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | Atezolizumab, Bevacizumab, Carboplatin, and Pemetrexed | ORR | 700 | Recruiting | NCT03178552 |
III | TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations | TAK-788 Versus Platinum-Based Chemotherapy | PFS | 318 | Recruiting | NCT04129502 |
III | A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC | Toripalimab combined with standard chemotherapy | PFS | 450 | Recruiting | NCT03856411 |
III | A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions | Amivantamab + Chemotherapy Versus Chemotherapy Alone | PFS | 300 | Recruiting | NCT04538664 |